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342 Abstract (212/250 words)
43 Carcinoid heart disease (CHD) is a consequence of valvular fibrosis triggered by vasoactive 
44 substances released from neuroendocrine tumours, classically in those with metastatic disease 
45 and resulting in tricuspid and pulmonary valve failure. CHD affects 1 in 5 patients who have 
46 carcinoid syndrome (CS). Valve leaflets become thickened, retracted and immobile, resulting 
47 most often in regurgitation that causes right ventricular dilatation and ultimately, right heart 
48 failure. The development of CHD heralds a significantly worse prognosis than those patients 
49 with CS who do not develop valvular disease. Diagnosis requires a low threshold of suspicion 
50 in all patients with CS, since symptoms occur late in the disease process and clinical signs are 
51 difficult to elicit. As a result, routine screening is recommended using the biomarker, N-
52 terminal pro-natriuretic peptide, and regular echocardiography is then required for diagnosis 
53 and follow-up. There is no direct medical therapy for CHD, but the focus of non-surgical care 
54 is to control CS symptoms, reduce tumour load and decrease hormone levels. Valve surgery 
55 improves long-term outcome for those with severe disease compared to medical 
56 management, although peri—operative mortality remains at between 10-20% in experienced 
57 centres. Therefore, care needs to be multidisciplinary at all stages, with clear discussion with 
58 the patient and between teams to ensure optimum outcome for these often-complex patients.
59
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460 Introduction
61 Neuroendocrine tumours (NETs) of gastrointestinal origin (GI NET) synthesise and release 
62 various hormones, including 5-hydroxytryptamine (5-HT). These hormones drain from the 
63 primary lesion and local lymph node metastases via the portal circulation into the liver, where 
64 they are degraded. When GI NETs have metastasised to the liver, retro-peritoneal lymph 
65 nodes or ovaries, the hormones released by-pass degradation in the liver and gain access to 
66 the systemic circulation, causing carcinoid syndrome (CS), consisting of facial flushing, 
67 diarrhoea and occasionally bronchospasm.(1) Primary NETs within the ovaries are 
68 uncommon but can also cause CS and CHD by direct release of bioactive amines into the 
69 inferior vena cava or renal vein. The hormones released by tumours are fibrogenic and cause 
70 scarring, most often in the right sided heart valves, resulting in regurgitation that ultimately 
71 leads to right ventricular (RV) dilatation and dysfunction. The left sided heart valves are 
72 likely protected by inactivation of pathological substances in the lungs. Left sided heart 
73 valves can be damaged either by transit of fibrogenic amines through a patent foramen ovale, 
74 or when the primary tumour is in the lung, or when hormonal release is over-whelming.(1) 
75 This entity is termed carcinoid heart disease (CHD).(2) CHD occurs in patients with 
76 advanced stages of cancer that is hormonally active. Its management is complex and 
77 challenging as patients usually present late, often with features of heart failure. Even when 
78 patients are diagnosed early, the onset and progression of CHD is unpredictable. Optimum 
79 management of the patient therefore requires close collaboration between multiple experts in 
80 order to: control carcinoid and cardiovascular symptoms, quantify disease burden, determine 
81 a strategy for medical and surgical management, optimise the patient for intervention, and 
82 maximise outcomes. This article draws on our experience of managing patients with CHD, 
83 suggesting that centralising care to a limited number of centres able to invest in the required 
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584 service development and having the appropriate infrastructure for multidisciplinary care may 
85 be the best way to improve outcomes for CHD patients.
86
87 Pathophysiology of CHD
88 In order to manage CHD, it is vital to understand the underlying anatomy of the heart valves 
89 and how the disease alters the tissue architecture. Valve interstitial cells (VIC) are the most 
90 abundant cells in heart valves; they maintain structural integrity and are found dispersed 
91 throughout the three layers: the fibrosa, spongiosa and ventricular/atrial layers. These three 
92 layers have different compositions: the fibrosa is rich in collagen, the spongiosa is rich in 
93 proteoglycans and the ventricular/atrial layer is dense in elastin. These layers are then 
94 covered by valve endothelial cells (VEC). (Figure 1) (3) Studies have shown that an 
95 accumulation of VICs associated with inflammatory cells, neovascularisation, increased 
96 matrix production and eventually fibrosis and calcification, occurs in response to valvular 
97 injury.(4) In diseased valves, VICs become activated to regulate repair and valve 
98 remodelling.(5)
99
100 There are five different phenotypes in the VIC group: embryonic progenitor endothelial / 
101 mesenchymal cells, quiescent VICs (qVICs), activated VICs (aVICs), progenitor VICs 
102 (pVICs) and osteoblastic VICs (obVICs).(6) The embryonic progenitor endothelial / 
103 mesenchymal cells undergo endothelial to mesenchymal transformation (EMT). Individual 
104 endothelial cells then migrate into the endocardial cushion resulting in the transformation of 
105 endothelial cells into mesenchymal cells, and matrix remodelling occurs in the cushion to 
106 develop into mature heart valves.(6, 7) It is thought that the EMT process also occurs after 
107 post-natal development in adult valves following injury and valve disease. The VECs on the 
108 cushion surface contain properties of the valve progenitor cells and may result in VICs 
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6109 formation which then participate in valve repair.(8)
110
111 The qVICs are in the heart valve leaflet, maintain valve structure and function, and generally 
112 keep the valve avascular by inhibiting angiogenesis. In response to valve injury, qVICs 
113 become activated and also give rise to aVICs to enable valve repair and remodelling to take 
114 place.(4) The pVICs are valvular stem cells derived from various origins, and are found in the 
115 bone marrow, circulation, and heart valve leaflet. They consist of two cell types: endothelial 
116 progenitor cell (EPC) and dendritic cell (DC). EPC is identified by the stem cell markers 
117 CD133 and CD34, are highly proliferative and are able to form new blood vessels.(6, 9) DCs 
118 are identified by the intracellular calcium binding protein, S100.(8) In response to injury, 
119 pVICs including the circulating cells, bone marrow derived cells and the resident valvular 
120 progenitor cells are another source of aVICs. The aVICs responding to valve injury and 
121 disease take on characteristics of myofibroblasts but are not smooth muscles as they have 
122 incomplete basement membranes.(10) These cells are located in the heart valve leaflet. The 
123 aVICs are positive for -smooth muscle actin (-SMA) and lead to increased extracellular 
124 matrix production and degradation, MMP expression and tissue inhibitors of MMP 
125 expression, as well as increased proliferation and migration. These are all important factors in 
126 the repair process. These VICs also increase the secretion of cytokines, particularly 
127 Transforming Growth Factor  (TGF-). (6) The majority of aVICs are then discarded by 
128 apoptosis after remodelling has occurred.(11)When this process is dysregulated, aVICs 
129 survive resulting in abnormal extracellular matrix production and remodelling, pathological 
130 fibrosis, angiogenesis and neovascularisation and calcification, eventually leading to valve 
131 disease.(6, 11) The obVICs are also located in the heart valve leaflet too and may be derived 
132 from pVICs. They actively participate in the calcification process, and also cause 
133 chondrogenesis and osteogenesis in the heart valve.(6)
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135 NETs secrete a range of vasoactive substances, including 5-HT, prostaglandins, bradykinin, 
136 histamine, and substances containing fibroblast proliferative properties (such as substance P) 
137 or TGF that are thought to be involved in the pathogenesis.(12) 5-HT receptors play a major 
138 role in the development of CHD. These are present in the heart, with subtype 5-HT2B 
139 receptor being predominant.(13) Activation of these receptors results in mitogenesis of 
140 fibroblasts and smooth muscles cells, cytokine recruitment, and up-regulation of TGF.  
141 Another factor involved in the pathogenesis of this disease is deficiency of the 5-HT 
142 transporter which is involved in uptake of 5-HT and inactivation in the lungs.(2) This 
143 complex process results in the deposition of endocardial plaques, plaques in the chordae, 
144 papillary muscles and heart chambers, and occasionally within the vascular intima, including 
145 the pulmonary arteries and aorta.(12) These plaques are comprised of myofibroblasts, smooth 
146 muscle cells, extracellular matrix components including collagen, elastin and myxoid matrix, 
147 and an endocardial cell layer.(14) Classically, plaques involve the right side of the heart 
148 (around 90% of cases), likely due to pulmonary inactivation of the vasoactive substances, 
149 resulting in right heart failure.
150
151 Presentation, Clinical Assessment and Diagnosis
152 Cardiac symptoms and signs are often lacking or are subtle until CHD is advanced. Clinical 
153 examination lacks sensitivity in detecting valvular heart disease and is particularly poor in 
154 detection of the right-sided lesions that are common in CS, so should not be relied upon for 
155 screening of patients.(15) Electrocardiography (Figure 2) and chest radiography (Figure 3) 
156 are also unhelpful in the majority of patients with CHD, as changes are non-specific and 
157 often only detect advanced disease. N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
158 is a useful biomarker that should be checked in all patients with CS on a 6-monthly basis, and 
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8159 a cut-off level of 260ng/L has reasonable sensitivity for screening patients with a high 
160 negative predictive value.(16) NT-proBNP is a product of cleavage of a pro-hormone 
161 released predominantly from myocardial cells mainly in the atria in response to volume 
162 expansion (chamber dilatation) and increased wall stress, so it is not specific to CHD and 
163 may be elevated in patients with other co-morbidity, for example arrhythmia (atrial 
164 fibrillation) and coronary artery disease. Therefore, any patient with an elevated NT-proBNP 
165 should then undergo transthoracic echocardiography (TTE), which is the main modality for 
166 diagnosis of CHD.(Figure 4) Although scoring systems have been developed to improve 
167 accuracy of diagnosis on TTE, this is a technique that relies on the skill and experience of the 
168 operator in identifying the changes of CHD.(17) Therefore, in early cases when changes may 
169 be limited to loss of normal concave curvature of leaflets and mild thickening, diagnosis can 
170 be missed unless the operator is experienced and it may be useful to obtain reviews from 
171 those experienced in imaging patients with CHD.
172
173 Unfortunately, screening for CHD is frequently forgotten on initial presentation of patients 
174 with NET, or regular, repeat assessment then neglected.(18) As a result, NET patients with 
175 CHD often present late with advanced disease. Symptoms include a gradual reduction in 
176 exercise capacity, which is often wrongly attributed (by patients and physicians alike) to 
177 other things, such as ageing, the effects of metastatic NET or therapy thereof, until the 
178 development of signs of right heart failure, commonly swelling of the ankles. The tricuspid 
179 valve (TV) is affected in most patients, with the classical changes seen on 2D TTE including 
180 leaflet thickening, retraction, and reduction in mobility, usually resulting in regurgitation 
181 (TR) but sometimes with co-existing stenosis. (Figure 5) The pulmonary valve (PV) is 
182 involved in half of those with CHD, again most often with regurgitation (PR) but also 
183 occasionally with co-existing stenosis.(19) (Figure 6) By the time of presentation, the 
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9184 consequence of chronic, severe TR is right ventricular dilatation and dysfunction. TTE is the 
185 default modality for diagnosis, quantifying severity of valve lesions and measurement of the 
186 effects on the right ventricle (RV). Transoesophageal echocardiography (TOE) can be of 
187 added benefit when TTE views are suboptimal, particularly with the use of 3D to provide 
188 high quality imaging of the PV where all three cusps cannot be visualised on 2D alone. 3D 
189 TOE can improve visualisation of structural tricuspid valve defects.(20) (Figure 7) Left-sided 
190 valve disease affects a minority of patients, limited to those with a patent foramen ovale 
191 (PFO) that allows blood to avoid passage through the lungs, those with pulmonary 
192 metastases, and those with high tumour burden who may secrete such large volume of 
193 hormones that these overcome lung clearance.(21) Diagnosis of a PFO requires agitated 
194 saline TTE to detect early passage of contrast from the right side of the heart to the left, 
195 which is vital in pre-surgical assessment to ensure closure at the time of operation.(Figure 8)
196
197 In those patients diagnosed with CHD that is not severe, review should be performed on a 6-
198 monthly basis, as progression of valve disease is not linear and can be rapid.(22) Faster 
199 progression of CHD is more likely in those with clinical and biochemical evidence of active 
200 CS, although radiological burden of NET does not appear to be associated with advancing 
201 CHD. Moller et al found that progression of CHD was proportionately faster for each 25mg 
202 increase in urine 5HIAA and also faster in those who had received prior cytotoxic 
203 chemotherapy, although the latter may have been a marker for those with more aggressive 
204 disease.(23) Bhattacharyya et al found that those with urine 5HIAA levels >300umol/24 
205 hours or active flushing more than 3 times per day likewise had an increased risk of 
206 progression.(24) Likewise, Dobson et al also found faster progression in those with unstable 
207 symptoms, defined by a >50% increase in frequency of flushing or bowel movements, and 
208 each increment >100nmol/L-1 in plasma 5HIAA.(22) In those with established CHD, TTE 
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209 should be considered every 6 months, although alternating with cardiovascular magnetic 
210 resonance (CMR) imaging can be advantageous when tracking change in RV size and 
211 function, since this is more reliable and reproducible than 2D or 3D TTE.(22, 25) (Figure 9) 
212 There are no therapies that directly retard or reverse the progression of CHD but there is 
213 indirect evidence from the reduction in rate of CHD since the introduction of somatostatin 
214 analogues and the factors associated with faster progression that reduction in CS activity is 
215 likely to be important. It is not known whether there is a ‘threshold target’ for lowering 
216 5HIAA to minimise progression of CHD but suppression of active flushing and stability of 
217 bowel movements may be a reasonable aim.
218
219 Recommendations on Presentation, Clinical Assessment and Diagnosis:
220 1. Presentation of patients with CHD is highly variable but is often late;
221 2. Clinical examination is not a reliable way of screening for CHD;
222 3. All patients with raised plasma/urine 5HIAA should be screened annually for CHD;
223 4. Screening should be with NT proBNP and those with levels>260ng/L should undergo 
224 transthoracic echocardiography;
225 5. Patients with CHD should be referred to a Cardiologist and seen every 6 months.
226
227 Medical Management of CHD
228 Treatment of CHD should be multidisciplinary, as there are competing demands of both CHD 
229 and NET. In some patients, surgery for CHD may be the priority to ensure the survival and 
230 fitness of the patient to then pursue more aggressive treatment of the NET. In others however, 
231 the patient may need stabilisation of CS with reduction of tumour load before surgery for 
232 CHD can be more safely undertaken.
233
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234 Pharmacotherapy for CHD and CHF. Once patients have developed effort intolerance or 
235 signs of right heart failure, the introduction of a thiazide or loop diuretic is usually beneficial 
236 to improve exercise intolerance and reduce peripheral oedema and ascites. Any improvement 
237 should neither be taken as a sign that all is well, nor that further action can be delayed, as the 
238 period during which the patient will remain stable is of variable duration and this time should 
239 be used to assess the patient for valve surgery. There is no evidence of benefit of standard 
240 heart failure therapy such as angiotensin-converting enzyme inhibitors, angiotensin-receptor 
241 antagonists or beta-blockers in RV dilatation and dysfunction in CHD. Moreover, treatment 
242 of RV failure in the context of right heart valve failure is difficult, as depletion of 
243 intravascular volume and pooling due to hypotension can further impair cardiac output.
244
245 Management of Carcinoid Syndrome. CS is best treated starting with somatostatin analogues 
246 (SSAs) in the form of long acting preparations; Sandostatin LAR® or Lanreotide autogel®. 
247 These are given every 4 weeks and are effective in improving CS by reducing the release of 
248 hormones, such as 5-HT, by tumour cells. While these agents are of great use in patients with 
249 CS, there are no data to suggest that these either cause regression or prevent progression of 
250 CHD, and no evidence of improvement in survival in CHD.(23) By the time of onset of 
251 CHD, standard dosages of SSAs begin to lose efficacy in managing symptoms. At this point, 
252 the frequency of injections should be increased from the standard 4 weekly to 3- or 2-weekly. 
253 Short acting octreotide given subcutaneously 3 times daily can provide additional relief. If 
254 these measures are not enough, then the following steps can be considered (see Table 1)
255 1. Intravenous octreotide starting at 50mcg/hr and increasing to 500mcg/hr if required;
256 2. Alpha Interferons, although highly effective in some patients at improving CS 
257 symptoms, can be difficult to obtain. While they may be of use in patients with CS, there are 
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258 no data to suggest that alpha interferons either cause regression or prevent progression of 
259 CHD, and no evidence of improvement in survival in CHD.
260 3. Telotristat ethyl (250mg tds) is approved for diarrhoea related to CS and works by 
261 inhibiting tryptophan hydroxylase, thereby reducing 5-HT biosynthesis. There is evidence of 
262 efficacy in reduction in urinary 5-hydroxyindoleacetic acid and in control of CS, and is used 
263 for this indication but without evidence relating to stability of CHD itself.(26)
264 4. Trans-Arterial Embolisation (TAE) can be used with caution in the presence of RV 
265 failure. It may be safer to perform TAE piecemeal, with anaesthetic cover and recovery in 
266 HDU/ITU.
267 5. Surgical Reduction of Tumour Burden in NETs. Surgical resection of the primary 
268 tumour and removal of hepatic metastases can be an option in the few patients who do not 
269 have a high burden of liver disease. While such surgery can be useful both in preventing 
270 progression of CHD and improving prognosis, surgery on the liver is usually precluded in the 
271 presence of right heart failure.(27) High right heart pressures as seen in severe TR increase 
272 the risk of bleeding intra-operatively owing to the increase in back pressure through the 
273 valve-less venous system of the liver. Furthermore, high right heart pressures can also 
274 hamper venous outflow and may compromise the ability of the liver to regenerate after 
275 surgery. Surgical reduction in tumour load by operating on other areas responsible for CS 
276 however, such as the ovaries, may be possible. Liver surgery may become feasible after valve 
277 replacement.
278
279 Nutrition: Optimising the Patient for Surgery. Key factors in our experience which influence 
280 30-day outcome following surgery have been control of CS symptoms (see earlier) and 
281 ensuring optimisation of nutrition with stabilisation of weight. This is a key facet of the 
282 involvement of the NET specialists in the pre-operative optimisation of the patient, and either 
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283 instability in CS or an active catabolic state would be reasons accepted for delay in 
284 cardiothoracic surgery. There is a high prevalence of malnutrition amongst cancer patients 
285 and this is associated with poorer outcomes and reduced survival.(28) Studies have shown 
286 that 28-58% of patients with NETs are at nutritional risk, with higher incidence in those with 
287 a GI-NET compared to those with bronchial NET. (26, 29) It is widely understood that 
288 malnutrition is associated with poorer outcomes in terms of increased complication rates 
289 post-surgery, increased length of stay, decreased response to treatment, higher in-patient 
290 mortality and poorer quality of life.(30)
291
292 The cause of malnutrition in patients with NETs is likely to be multifactorial and may 
293 include; reduced oral intake, malabsorption, diarrhoea and increased total energy expenditure. 
294 Patients with a poor oral intake should be offered individualised dietary assessment and 
295 counselling and may require oral nutritional supplements or possibly artificial nutrition 
296 support. It is thought that sarcopenia and thus reduced muscle mass rather than loss of fat 
297 mass, has the greatest impact on outcomes in patients with cancer. It therefore seems prudent 
298 to ensure patients are achieving an optimal protein intake, with attention paid to protein 
299 distribution and frequency of ingestion as these have been shown to play an important role in 
300 preserving muscle mass and function, with a recommended protein target of 1-
301 1.5g/kg/day.(31) Niacin (Vitamin B3) deficiency affects a quarter of patients with CS owing 
302 to increased tryptophan metabolism for serotonin production, and supplementation of 25-
303 50mg a day is therefore recommended in patients with CS.(32) Where patients are 
304 experiencing symptoms suggestive of malabsorption such as diarrhoea, steatorrhea, 
305 borborygmi, flatus, bloating and pain after eating, measures should be taken to identify and 
306 treat the cause of this. Nutritional support in the presence of untreated malabsorption is likely 
307 to be futile. A summary of nutritional recommendations is listed in Table 2.
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308
309 Recommendations on Medical Management of CHD:
310 1. There are no current non-invasive treatments for CHD;
311 2. Diuretics improve symptoms but pharmacotherapy is palliative;
312 3. Control of carcinoid symptoms and suppression of plasma/serum/urine 5HIAA should 
313 be a focus in those with CHD, usually requiring high dose somatostatin analogue 
314 therapy.
315 4. Patients under consideration for surgery for CHD need to be in an optimal nutritional 
316 status and formal dietetic input is required.
317
318 Surgery for CHD
319 Indications for Surgery. The current accepted indications for valve replacement include 
320 severe valve regurgitation or stenosis with symptoms of effort intolerance or right heart 
321 failure.(2) Rarely, patients have had valve surgery in our service in preparation for potentially 
322 curative resection of primary and metastatic disease or for major palliative intervention. 
323 Given that patients will usually be on Intensive Care for 24-48 hours, in hospital for 7-10 
324 days, but will then take 6-12 weeks to recover from surgery, the expectation is that those who 
325 go through surgery should have a life expectancy of at least 12 months. Once patients are 
326 symptomatic with CHD, prognosis deteriorates quickly and peri-operative risk increases with 
327 delay, so our practice is to admit patients as soon as possible for work-up and review over 
328 one week. The patient’s case is then discussed within a multidisciplinary meeting involving 
329 Cardiologist, Cardiothoracic anaesthetist, Cardiothoracic surgeon, NET physician and NET 
330 specialist nurse all experienced in the field of CHD. Valve surgery should then be performed 
331 as quickly as is feasible, once any hurdles are overcome, the main ones being control of CS, 
332 nutrition, and physical disability.
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333
334 Choosing the Patient for Surgery: Cardiothoracic surgery to replace valve disease is the only 
335 effective treatment for advanced CHD but causes morbidity, requires time for recovery and 
336 continues to carry a significant risk of death within 30 days. At present, transcatheter 
337 techniques have not been used to treat CHD of native valves although their use is increasing 
338 in other aetiologies.(33) Although early reports suggested very high peri-operative mortality 
339 during surgery for CHD, serial data have suggested improved outcomes over time in centres 
340 with experience and 30-day mortality is now much lower.(34, 35) A series of studies have 
341 published results in this area that are summarised in Table 3, which reflect that as with all 
342 cardiovascular intervention, outcomes improve with increased knowledge about the disease 
343 and with volume of procedures performed.(36-39) (40-45) Those patients who proceed with 
344 surgery have a 1 year survival of 75% compared with 45% for those who have an indication 
345 for surgery for CHD but do not proceed.(34) There is a lack of data that identifies those at 
346 greatest risk of major morbidity and mortality within 30 days of surgery but in our 
347 experience, those factors which are particularly important in deciding which patients will 
348 survive include age, failure of the RV after TV replacement (which removes the ‘off-loading’ 
349 of a failing ventricle), haemodynamic instability from uncontrolled CS, and on-going weight 
350 loss before surgery. Although data are not available specifically from peri-operative 
351 outcomes in NET-CHD patients, there are extensive data highlighting both weight loss and 
352 low serum albumin as predictors of worse outcomes following general surgery.(46) There are 
353 data on surgical outcomes in patients with pancreatic cancer that survival was reduced in 
354 those with weight loss of more than 10%.(47) In our practice, we consider a weight loss of 
355 10% compared to stable pre-illness weight to be significant in NET-CHD.
356 A list of factors taken into consideration by the team is outlined in Table 4.
357
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358 Valve Surgery. Surgery primarily involves replacement of any valve with severe 
359 regurgitation or stenosis, together with closure of PFO if present. Given the unpredictable 
360 rate of progression of CHD, replacement of moderately affected valves is also usually carried 
361 out at the same sitting, although this decision is a balance between increased risk of 
362 prolonged surgery against the risk of potential progression if a valve is left untouched. 
363 Rarely, patients can have all four valves replaced leading to symptomatic improvement – but 
364 risk is high and the physical condition of the patient taken on for multiple valve surgery must 
365 otherwise be excellent.(48) Bioprosthetic valve replacements are chosen in preference to 
366 mechanical valves, as these mean the patient can avoid long-term anticoagulation, are at 
367 lower risk of valve thrombosis in the right heart, and have a better haemodynamic 
368 profile.(49) Furthermore, consistent with the European Society of Cardiology guidelines, the 
369 choice of a bioprosthetic valve is also based on the consideration that the life expectancy of 
370 the NET patient with CHD is likely to be lower than the expected durability of the valve.(50) 
371 Valves commonly used in practice include the Carpentier Edwards Perimount stented bovine 
372 prosthesis and the Hancock II porcine prosthesis, both of which have excellent long-term 
373 durability with rates of structural valve degeneration below 2% at 10 years and 15% at 20 
374 years in left heart disease.(51) PV replacement often requires patching of the pulmonary 
375 artery with bovine pericardium, as an adequate annulus size is critical to minimise afterload 
376 on the RV following surgery. Coronary artery by-pass grafting is performed in a minority of 
377 patients, limited to those with major epicardial stenosis > 70%.(34) Surgery to the TV risks 
378 damage to the conduction system and the subsequent implantation of a permanent pacing 
379 wire through a functioning TV replacement is a disaster in CHD patients, so our practice to-
380 date has been implantation of epicardial wires at the time of operation. This has the 
381 disadvantage that subsequent imaging follow-up has to be restricted to echocardiography, 
382 since CMR carries undefined risk and may not produce adequate image quality for 
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383 analysis.(52) 
384
385 Recommendations on Surgery for CHD
386 1. Valve replacement should be performed in symptomatic patients with severe CHD;
387 2. Valve replacement should be performed in asymptomatic patients with severe CHD 
388 who have evidence of progressive ventricular dilatation or impaired ventricular 
389 function;
390 3. Any patient undergoing surgery on any valve for CHD should be tested for a patent 
391 foramen ovale and if present, this should be closed at time of operation.
392 4. Valve replacement should not be performed in patients with life expectancy of less 
393 than 12 months and should be delayed in those pending control of active carcinoid 
394 syndrome or reversal of a catabolic state.
395 5. Bioprosthetic (xenograft) valves should be used;
396 6. Surgery should be performed that minimises any requirement for implantation of 
397 transvalvar pacing wires, including prophylactic implantation of epicardial wires.
398
399 Peri-Operative and Post-surgical care. A major factor in terms of optimising outcome from 
400 valve surgery is the involvement throughout the patient pathway of Cardiothoracic 
401 Anaesthetists experienced in dealing with CS and patients with NET. The details of 
402 management in the peri-operative phase are outlined in Appendix 1. Following surgery, all 
403 patients are returned to a specialist Cardiac Intensive Care Unit (ICU). Patients receive an 
404 octreotide infusion that is started before induction and is continued until the patient is 
405 haemodynamically stable and off inotropes. At the time of operation whilst the right atrium is 
406 still open, a pulmonary artery catheter is passed through the TV and PV into the right 
407 pulmonary artery for monitoring of cardiac output on ICU. This helps to guide inotropic and 
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408 vasopressor support post-operatively. The patients are weaned from the ventilator and 
409 extubated as soon as it is clinically appropriate, since ventilation increases afterload on the 
410 RV and can further hinder contractility.
411
412 From the ICU, the patients are stepped down to a specialist Cardiothoracic Surgical ward for 
413 daily post-operative review, including regular physiotherapy and NET team assessment. 
414 Patients following surgery for CHD with bioprosthetic valve replacements are routinely 
415 commenced on warfarin anti-coagulation for 6 months, depending on risk assessment of 
416 bleeding, with the aim of minimising formation of microthrombi and preventing structural 
417 valve degeneration.(50) Although there is evidence that non-vitamin K oral anticoagulants 
418 are superior to warfarin for the prevention of stroke and systemic embolism in non-valvar 
419 atrial fibrillation, only retrospective analyses have been performed in patients with atrial 
420 fibrillation and valve disease, including bioprosthetic valve replacements. While meta-
421 analyses of these retrospective data suggest equivalent outcomes in terms of stroke and 
422 systemic embolism to warfarin, there are not data on the relevant efficacy for prevention of 
423 structural valve disease.(53) Warfarin therefore continues to be used for this indication. 
424 Thereafter, patients are continued lifelong on aspirin 75mg od to reduce the recognised risk 
425 of early valve thrombosis and failure.(35) A formal baseline echocardiogram following 
426 surgery is essential against which to compare future studies to detect structural valve 
427 deterioration and complications. This sometimes may be performed within the surgical stay 
428 but study within 6-8 weeks is ideal to ensure optimal image quality. (54)
429
430 Follow-Up. All patients require lifelong follow-up by a cardiologist specialising in NET after 
431 valve surgery for CHD to detect early deterioration in prosthetic function, altered ventricular 
432 function or progressive disease of another heart valve.(50) While this is consistent with 
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433 current guidelines for the post-operative management of patients with all valve disease, this is 
434 particularly important in those with CHD. Given the unpredictable progression of CHD, our 
435 practice is for clinical assessment on a 6-monthly basis, with echocardiography performed on 
436 an annual basis to track change in ventricular function, increase in replacement valve 
437 velocities and the development of new valve lesions. A major risk for right heart valve 
438 replacements is valve thrombosis, although abrupt valve failure is uncommon. More usual is 
439 a gradual, asymptomatic serial increase in velocity in the absence of regurgitation, with 
440 velocities increasing above those performed on a routine pre-discharge echocardiogram.(55) 
441 Even if asymptomatic, further investigation is warranted, although transoesophageal imaging 
442 is often required to determine change in leaflet thickness, mobility, and visualisation of 
443 thrombus. Multidetector gated computed tomography may also be used as there is evidence 
444 this may be more sensitive.(56) A second risk for patients following valve replacement for 
445 CHD is that of recurrent disease.(35) Efforts have to be made to minimise CS by optimising 
446 control of NET.(57) Under these circumstances, re-do valve surgery makes peri-operative 
447 risk unpalatable in many cases, although percutaneous valve-in-valve replacements can offer 
448 good clinical outcomes.(58) Thirdly, patients with bioprosthetic valve replacements for CHD 
449 are at increased risk of infective endocarditis, particularly if immunocompromised, and serial 
450 reminders are given regarding the need for regular dental assessment and good dental hygiene 
451 throughout follow-up. Antibiotic prophylaxis should be considered for high-risk procedures 
452 in CHD patients with prosthetic valves, including dental procedures involving manipulation 
453 of the gingival or periapical region of the teeth or manipulation of the oral mucosa.(59)
454
455 Recommendations on Post-Surgical Care in CHD
456 1. Peri-operative, intensive and post-surgical care requires highly specialised care from 
457 members of the whole multidisciplinary team with expertise in CHD;
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458 2. CHD patients with bioprosthetic valves should be anti-coagulated with warfarin for 6 
459 months and should remain lifelong on an anti-platelet agent thereafter;
460 3. Transthoracic echocardiography should be performed within 6-8 weeks of discharge 
461 following valve replacement;
462 4. All patients following valve replacement for CHD require regular review at 6-
463 monthly intervals, with echocardiography performed on an annual basis.
464 5. Increased transvalvar velocities or de novo regurgitation through bioprosthetic valves 
465 should prompt consideration of structural valve deterioration and consideration of re-
466 introduction of anti-coagulation.
467
468 Nursing Care
469 NET clinical nurse specialists (CNSs) have comprehensive expertise in managing all aspects 
470 of patient care and provide the ‘bigger picture’. Their role as a ‘key worker’ facilitates care 
471 by the large multi-disciplinary team.(60) The NET CNSs monitor patients for worsening of 
472 CS, development of CHD and can rapidly identify emerging clinical issues by being an 
473 immediate, accessible resource for the patient. They also focus on the holistic management of 
474 patients. Onset of CHD can lead to increased fatigue, and the psychological impact of CHD 
475 can be distressing for both patients and families. Effective and timely communication with 
476 the patient and family ensures they are well informed, which reduces stress and anxiety for 
477 the patient and family.(61) Patients allocated a CNS are more positive about the experience 
478 of their care, potentially because patients supported by a CNS receive holistic care that 
479 includes emotional and practical support as well as addressing physical needs. Often patients 
480 can build closer bonds with their CNS and ask questions which they may not want to ask 
481 their doctor.(60)
482
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483 Adopting a standardised approach to care and developing robust protocols and pathways 
484 helps with the induction of new members of the MDT. A key role for the CNS is in 
485 reinforcing patient safety by ensuring such protocols and pathways are well known and 
486 closely followed. The education of the wider care team regarding management of CS and 
487 CHD is a further focus for the CNS, including development and dissemination of 
488 comprehensive Carcinoid Management Guidelines that are widely available and shared with 
489 referring teams, further providing guidance and support. The CNS provides specialist 
490 education and training to other professionals involved in patient care to facilitate effective 
491 clinical practice across the MDT disciplines.
492
493 As the CNSs have knowledge and insight into the entire patient pathway, they are often able 
494 to influence care at key stages within the patient journey. This is fundamental to appreciation 
495 of the role of the CNS,(62) and endorses their contribution to the development of policy and 
496 clinical guidelines. CNS participation in multi-professional meetings ensures that nursing 
497 views are represented, but most importantly, they act as the patient advocate, keeping them at 
498 the heart of all we do.(63)
499
500 Recommendations on Nursing Care in CHD
501 1. Clinical nurse specialists act as key workers representing the patient;
502 2. Clinical nurse specialists ensure holistic care;
503 3. Nursing staff provide accessible education to both the patient and staff about 
504 neuroendocrine tumours, carcinoid syndrome and CHD.
505
506 Prognosis and Research Needs
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507 Although NETs are generally considered to have a benign course, patients with CHD do not 
508 live as long as those without CHD.(19) Moreover, prognosis deteriorates according to the 
509 severity of the CHD.(64) Although surgery provides an opportunity to improve symptom 
510 status and is thought to increase life expectancy, there are no effective medical therapies that 
511 prevent or inhibit progression of CHD. Further research is needed in this rare but complicated 
512 disease with adverse outcomes.(see Table 5) Firstly, the link between high circulating levels 
513 of 5-HT in NET and the development of CHD is supported by several animal models either 
514 involving the injection of primary NET tumour cells or direct administration of serotonin. 
515 Newer hormonal therapies like telotristat, which have been shown to drastically reduce 
516 serotonin levels may hold promise in altering disease course in CHD, although evidence in 
517 this regard is scant.(26, 65) Despite this however, the development of CHD cannot be 
518 explained by the sole presence of high levels of vasoactive substances in the circulation as the 
519 incidence of CHD is highly variable in patients with similar levels of 5HIAA (66). Further 
520 work is therefore required to understand the pathogenesis of this condition, specifically to 
521 understand what are the potential co-factors that drive fibrosis progression in the setting of 
522 high 5HIAA levels. Identification of these factors could help in patient stratification for 
523 treatment and help in the development of new therapeutic targets. Secondly, there is a need to 
524 better understand the risks and benefits of cardiothoracic surgery in CHD, and in predicting 
525 the outcome of patients with CHD to ensure the best short and long-term outcomes for 
526 patients.
527 Recommendations for Research
528 1. Identification of key fibrogenic markers and pathways in the valve tissue and blood 
529 from patients with CHD to guide patient risk stratification and the development of 
530 new therapies.
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531 2. Development of preclinical models that are more representative of the clinical context 
532 ie organoids with primary human tissue that can be used to test novel therapies.
533 3. Identification of novel tracers and nuclear medicine imaging to identify early fibrotic 
534 changes in valves.
535 4. Identification of clinical factors/scores that will predict RV function post-TVR and 
536 per-operative mortality in order to support improved patient selection for surgery.  
537
538 Conclusions
539 The presence of heart disease in a patient with CS confers a significantly worse prognosis 
540 compared to those without valvular heart disease. Clinical presentation is often late, as 
541 adherence to regular screening with biomarkers and echocardiography is incomplete. In those 
542 presenting with symptomatic CHD, control of symptoms with careful fluid management and 
543 diuretic therapy can help initially but valve replacement is the only treatment that can 
544 improve outcome. Surgery should always be considered regardless of metastatic disease, but 
545 peri-operative risk remains significant. Under these circumstances, optimal care is provided 
546 by close collaboration across multiple sub-specialties in centres with experience in 
547 management.
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562 Figure 1: Schematic diagram illustrating the valve layers.
563
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564 Figure 2. Electrocardiogram of a 75-year old male who was diagnosed with GI-NET 5 years 
565 after developing symptoms. He presented with active weight loss, severe diarrhoea and 
566 flushing. At the time of presentation, the patient had severe tricuspid regurgitation, severe 
567 pulmonary regurgitation, with right ventricular dilatation and impairment. His resting 12-lead 
568 ECG demonstrate sinus rhythm with normal axis but ECG criteria for incomplete right 
569 bundle branch block with an rSR complex in V1.
570
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571 Figure 3. Chest radiograph of a 74-year old male who was diagnosed with GI-NET in 2015 
572 and found to have elevated NT proBNP, which was attributed to age and hypertension 
573 without evidence of CHD. He remained under follow-up, developing tricuspid regurgitation 
574 that became severe and was associated with breathlessness. He was found however, to have a 
575 right pleural effusion that was exudative, without cellular infiltrate and with normal high-
576 resolution computed tomogram and with normal thoracoscopy.
577
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578 Figure 4. Apical four-chamber view from a transthoracic echocardiogram demonstrating the 
579 hallmark features of thickening, restriction of motion and retraction of the tricuspid valve 
580 leaflets, indicated by the arrow. The image has been frozen at end-systole, before the atrio-
581 ventricular valve leaflets should be open but, in this case, the tricuspid valve leaflets are 
582 clearly open at a time when the mitral valve leaflets are closed. LV=left ventricle; LA=left 
583 atrium; RV=right ventricle; RA=right atrium.
584
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585 Figure 5. Tilted parasternal long axis view from a transthoracic echocardiogram using colour 
586 Doppler to demonstrate severe, central tricuspid regurgitation into the right atrium due to 
587 carcinoid heart disease. RV=right ventricle; RA=right atrium.
588
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589 Figure 6. Tilted parasternal long axis view from a transthoracic echocardiogram using 2D 
590 (left panel) and colour Doppler (right panel) in a side-by-side format to demonstrate flow 
591 acceleration (indicated by the arrow) through fixed, retracted pulmonary valve leaflets, with 
592 the branch pulmonary arteries at the bottom of the image. RVOT=right ventricular outflow 
593 tract; MPA=main pulmonary artery.
594
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595 Figure 7. Mid-oesophageal long axis view of the pulmonary valve from a transoesophageal 
596 echocardiogram using colour Doppler to demonstrate severe pulmonary regurgitation 
597 (indicated by the arrow) that could not be identified in a 73-year-old ex-smoker with limited 
598 transthoracic acoustic window. AV=aortic valve; RVOT=right ventricular outflow tract; 
599 MPA=main pulmonary artery.
600
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601 Figure 8. Agitated saline contrast transthoracic echocardiogram from the apical four chamber 
602 view after release of Valsalva, with contrast seen in the left ventricle within 3 RR cycles from 
603 injection (the arrow indicates the ultrasound reflected from agitated saline giving the ‘white’ 
604 appearance within the ventricular cavity, compared to the black myocardium adjacent). This 
605 was a large patent foramen ovale in a 58-year-old female with symptomatic severe tricuspid 
606 regurgitation and right-to-left shunting at rest resulting in hypoxia that required device 
607 closure. LV=left ventricle; LA=left atrium.
608
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609 Figure 9. A contiguous stack of short axis steady-state free precession cine images is acquired 
610 through the long axis of the left and right ventricles, with annotation to demonstrate 
611 endocardial delineation from which end-diastolic (and end-systolic volumes: not shown) 
612 volumes are created.
613
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614 Table 1: Management of Carcinoid Syndrome in the Patient with Carcinoid Heart Disease
615
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616 Table 2: Nutritional Management in CS and CHD
617
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618 Table 3: Surgical Outcomes in NET-CHD
619
620
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621 Table 4: Factors Considered in Selection of the Patient for Valve Surgery.
622
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623 Table 5: Future Research Priorities in CHD
624
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 Figure 1: Schematic diagram illustrating the valve layers. 
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 Figure 2. Electrocardiogram of a 75-year old male who was diagnosed with GI-NET 5 years after developing 
symptoms. He presented with active weight loss, severe diarrhoea and flushing. At the time of presentation, 
the patient had severe tricuspid regurgitation, severe pulmonary regurgitation, with right ventricular 
dilatation and impairment. His resting 12-lead ECG demonstrate sinus rhythm with normal axis but ECG 
criteria for incomplete right bundle branch block with an rSR complex in V1. 
297x174mm (96 x 96 DPI) 
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 Figure 3. Chest radiograph of a 74-year old male who was diagnosed with GI-NET in 2015 and found to have 
elevated NT proBNP, which was attributed to age and hypertension without evidence of CHD. He remained 
under follow-up, developing tricuspid regurgitation that became severe and was associated with 
breathlessness. He was found however, to have a right pleural effusion that was exudative, without cellular 
infiltrate and with normal high-resolution computed tomogram and with normal thoracoscopy. 
174x165mm (96 x 96 DPI) 
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 Figure 4. Apical four-chamber view from a transthoracic echocardiogram demonstrating the hallmark 
features of thickening, restriction of motion and retraction of the tricuspid valve leaflets, indicated by the 
arrow. The image has been frozen at end-systole, before the atrio-ventricular valve leaflets should be open 
but, in this case, the tricuspid valve leaflets are clearly open at a time when the mitral valve leaflets are 
closed. LV=left ventricle; LA=left atrium; RV=right ventricle; RA=right atrium. 
338x254mm (96 x 96 DPI) 
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 Figure 5. Tilted parasternal long axis view from a transthoracic echocardiogram using colour Doppler to 
demonstrate severe, central tricuspid regurgitation into the right atrium due to carcinoid heart disease. 
RV=right ventricle; RA=right atrium. 
338x254mm (96 x 96 DPI) 
Page 48 of 61Accepted Manuscript published as EC-19-0413.R1. Accepted for publication: 11-Nov-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 11/22/2019 04:04:19PM
via free access
 Figure 6. Tilted parasternal long axis view from a transthoracic echocardiogram using 2D (left panel) and 
colour Doppler (right panel) in a side-by-side format to demonstrate flow acceleration (indicated by the 
arrow) through fixed, retracted pulmonary valve leaflets, with the branch pulmonary arteries at the bottom 
of the image. RVOT=right ventricular outflow tract; MPA=main pulmonary artery. 
338x254mm (96 x 96 DPI) 
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 Figure 7. Mid-oesophageal long axis view of the pulmonary valve from a transoesophageal echocardiogram 
using colour Doppler to demonstrate severe pulmonary regurgitation (indicated by the arrow) that could not 
be identified in a 73-year-old ex-smoker with limited transthoracic acoustic window. AV=aortic valve; 
RVOT=right ventricular outflow tract; MPA=main pulmonary artery. 
338x254mm (96 x 96 DPI) 
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 Figure 8. Agitated saline contrast transthoracic echocardiogram from the apical four chamber view after 
release of Valsalva, with contrast seen in the left ventricle within 3 RR cycles from injection (the arrow 
indicates the ultrasound reflected from agitated saline giving the ‘white’ appearance within the ventricular 
cavity, compared to the black myocardium adjacent). This was a large patent foramen ovale in a 58-year-
old female with symptomatic severe tricuspid regurgitation and right-to-left shunting at rest resulting in 
hypoxia that required device closure. LV=left ventricle; LA=left atrium. 
338x254mm (96 x 96 DPI) 
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 Figure 9. A contiguous stack of short axis steady-state free precession cine images is acquired through the 
long axis of the left and right ventricles, with annotation to demonstrate endocardial delineation from which 
end-diastolic (and end-systolic volumes: not shown) volumes are created. 
392x254mm (96 x 96 DPI) 
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Intervention Dose Advantages Disadvantages
Additional 
octreotide
Given to optimise 
CS control as either 
50 – 100mcg/hr i.v. 
Or 
50 – 500mcg tds s/c
Provides additional 
control of CS 
symptoms. It is easy 
to administer and 
adjust 
Frequent injections 
can become 
uncomfortable when 
administered s/c 
Interferon alpha 
(alone or in addition 
to somatostatin 
analogues)(Oberg, 
2005)
Pegasys® 90 – 180 
mcg/week (other 
types and 
preparations of 
Interferon are no 
longer available in 
UK)
Reduces hormone 
secretion by tumours 
and CS symptoms
Only tolerated or 
effective in about 
half the patients. 
Declining 
availability
Telotristat (in 
addition to 
somatostatin 
analogues)(Pavel et 
al., 2018)
250mg tds Inhibits 5-HT 
synthesis, reduces 
5HIAA levels and 
improves diarrhoea. 
Role in reducing 
carcinoid crisis not 
evaluated yet
TACE (in addition 
to medical therapies)
NA Immediate and 
lasting improvement 
in 5HIAA levels and 
CS symptoms
Significant 
morbidity and 
mortality that is 
possibly worsened 
by right heart failure
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Lutetium peptide 
receptor targeted 
radionuclide therapy 
(Lu-
PRRT)(Strosberg et 
al., 2017)
7000MBq x 4 given 
at approximately 8 
weekly intervals
Excellent 
improvement in PFS 
and OS
Only improves 
5HIAA levels and 
CS symptoms 
sometimes. Takes 8-
10 months for a 
course of treatment 
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All patients with NETs should be screened for risk of malnutrition
Patients with stable weight, muscle mass and good function who are eating well should be 
advised to follow a healthy, balanced diet.
All patients who are at nutritional risk should be provided with specialist nutrition support.
Where oral nutritional intake is inadequate patients should be offered artificial enteral 
nutrition support (tube feeding). Where enteral nutrition is not appropriate or feasible 
patients should be considered for parenteral nutrition.
All patients with NETs should be screened for malabsorption and measures should be 
taken to normalise digestion where possible.
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Author Recruitment Number Age 30-Day 1 yr 
Survival
5 yr 
Survival
Follow-
Up
Complications
Robiolio 1972-1994 8 60 (33-
76)
5 (63%) 37% 31% Up to 12 
yrs
Connolly† 1985-1992 26 54 (25-
72)
9 (35%) 32% NA NA RVF; 
Bleeding
Moller† 1981-2000 87 57 (50-
64)
25% to 
9%
NA NA
Castillo 2001-2006 10 59+9 2 (20%) NA NA 3.1 (0.5-
6.25)
RVF; HRS
Bhattacharyya 2006-2010 22 60 (50-
65)
4 (18%) 56% NA 2.2 (0.7-
3.5
RVF; CC; 
Sepsis
Komoda 2000-2008 12 64 (56-
69)
2 (16.7%) NA NA Up to 
4.9yrs
NA
Mokhles 1993-2010 19 56+10 1 (5%) 12 (63%) 8 (43%) 2.3+2.3 Sepsis
Connolly† 1985-2012 195 61+11 20 
(10%)*
69% 35% Up to 
19yrs
Kuntze 2008-2014 39 66 (28-
84)
2 (5%) NA NA NA RVF
Edwards 2005-2015 32 68+8 4 (13%) 75% NA NA RVF
Yong 2012-2016 20 64 (29-
77)
2 (10%) 74% NA 2+1.5 RVF; LF
Mujtaba 2011-2016 9 61 (55-
70)
1 (11%) NA NA 2 (0.6-4.2) RVF
Data are mean ± SD, median (25–75th percentile), absolute (%)
*After 2000
†Single centre series at different time points
NA=Not available; RVF=Right ventricular failure; HPS=Hepatorenal syndrome; CC=Carcinoid crisis; LF=Liver failure
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Allocation Risk Assessment
Patient Older age
Gender
Weight loss/low BMI (inc 
trend)
Clinical records
Advanced symptom status NYHA
MLHF
Limited physical fitness Cardiopulmonary exercise 
test
Risk Factors Hypertension 24-hour ABP
Diabetes mellitus HbA1C
Smoking status
Co-morbidity Cerebrovascular disease Carotid Doppler
Peripheral vascular disease
Chronic lung disease Lung function tests
Chronic kidney disease Estimated GFR
Disease status Active carcinoid syndrome Symptoms, Urine 24-hour 
5HIAA
Disease progression CT Thorax, Abdomen, 
Pelvis (serial)
Duration of somatostatin 
analogue therapy
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Prognosis, including options 
for further NET therapy
Cancer behaviour – indolent 
or rapid progression
Procedure details Number, severity, location 
of valves affected
Echocardiography
Atrial communication Contrast echocardiography
RV size and function CMR
LV size and function CMR
Coronary artery disease Invasive angiography
Pulmonary pressure RHC
The above assessments are performed during admission and form part of the 
multidisciplinary data collected for review. Other factors and specialist opinions, for example 
in patients with retroperitoneal spread of NET leading to ureteric obstruction, would be 
invited to contribute.
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Diagnosis Frequency of biomarker measurement
Identification of novel circulating 
biomarkers which identify pathological 
factors driving valvular disease eg pro-
fibrotic markers, markers of 
neovascularisation.
Identification of novel tracers in nuclear 
medicine imaging to identify early fibrotic 
changes in valves.
Treatment Role of telotristat in preventing or delaying 
progression of CHD
Predictors of RV function post-TVR
Predictors of peri-operative mortality
Identify novel medical therapies that will 
prevent or reverse the progressive 
valvulopathy.  Eg targeting pro-fibrotic 
pathways.   
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Birmingham Anaesthetic Intra-Operative Management
1. An octreotide infusion should run throughout the procedure.
2. Avoid unsafe drugs, see safe drugs below:
3. In symptomatic patients, an additional top up of octreotide should be 
considered before induction of anaesthesia.
4. Use phenylephrine as vasopressor (not metaraminol, metaraminol is an 
indirect acting sympathomimetic drug which can result in hypotension via 
stimulating release of noradrenaline and bradykinin).
1st line inotropes + Vasoconstrictors:
Phenylephrine 10mg/50ml 5% dextrose or 
saline dose range 
Vasopression (max 6ml/hr)
Enoximone (max loading dose 0.25mg/kg)
2nd line inotropes + 
Vasoconstrictors: 
Noradenaline caution
Adrenaline with caution (see below)
5. Ensure a test dose is given before starting the infusion for adrenaline: 4mcg/ml 
(1ml from 2mg in 50ml diluted in 10ml). The cautious use of adrenaline is 
considered safe in presence of myocardial dysfunction, provided a test dose 
(4mcg) does not display severe persisting hypotension and octreotide is used 
in conjunction.
6. It is best to avoid noradrenaline as it activates kallikrein that releases 
bradykinin which can cause severe hypotension.
Standard induction 
drugs
Standard 
infusions
Safe drugs Unsafe Drugs
Consider alternative 
where possible
Phenylephrine
Ondansetron
Fentanyl
Etomidate
Midazolam 
Propofol
Rocurinium 
Pancuronium
Octreotide infusion 
(50-100mcg/ml) 
consider bolus pre-
induction
NO 
METARAMINOL
Octreotide 
100mcg/ml 
typically 50-
150mcg/hr, but 
may require up 
to 300mcg/hr (2)
Phenylephrine
Alfentanil
Fentanyl
Propofol
Aprotonin
Vasopressin max 
6ml/hr
Alfentanil 
All inhalation 
agents 
Etomidate
Cis-atarcurium
Fentanyl
Midazolam
Propofol
Remifentanil
Rocuronium
Vecuronium
Histamine releasing 
drugs
Atracurium 
Mivacurium
Morphine
Tramadol
Sympathomimetics 
Metaraminol 
Adrenaline
Noradrenaline
Dopamine
Isoprenaline
Suxamethonium
Thiopental
Page 60 of 61Accepted Manuscript published as EC-19-0413.R1. Accepted for publication: 11-Nov-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 11/22/2019 04:04:19PM
via free access
Carcinoid Crisis- Should Be Managed on an Intensive Care Unit
Carcinoid crisis is primarily treated with intravascular volume expansion, octreotide 
boluses and escalation of octreotide infusion.
Octreotide infusion:
- If not on octreotide start octreotide infusion at 100mcg/hour. If already on 
octreotide, the dose should be increased. The infusion rate can be escalated up to 
300mcg/hour in 50-100mcg increments. 
- An octreotide infusion must be used if starting inotropes 
If the patient continues to be unstable (↓BP, ↑HR, flushing), consider octreotide 
boluses 50-200mcg, diluted to 5ml of 0.9% normal saline. These bolus doses can 
be repeated every 5-10minutes.
Other medication that can help in severe cases (use intravenous injection)
- H1 receptor blockers (loratadine) and H2 blockers (ranitidine) may be required. 
- Corticosteroids (e.g. hydrocortisone 50mg IV QDS)
- Ondansetron (antiemetic) - occasionally controls flushing and diarrhoea 
- Chlorphenamine (10mg IV)
- Magnesium sulphate/GTN/ sodium nitroprusside (SNP) with ↑BP (caution, the 
precipitous drop in BP promotes endogenous catecholamine secretion)
Specific symptoms
Bronchospasm Increase octreotide infusion rate, steroids, ipratropium bromide 
nebuliser. Use β-agonists and theophylline with caution, can 
precipitate mediator release with deterioration in symptoms
Persistent flushing Indicates increased requirement of octreotide infusion
Hyperglycaemia Monitoring blood glucose is advisable in patients with known 
diabetes or those requiring high dose octreotide. May require 
temporary IV insulin.
Hypertension Octreotide + fentanyl.  (Hypertensive crisis can be treated with 
boluses of Octreotide, SNP and GTN)
Hypotension Octreotide + Fluid + Trendelenberg position (caution if 
epidural)
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